NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-208-2023-0-AU-01 HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES AU National Stage 2022399574 Pending
NEI E-076-2023-0-PC-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS PCT PCT PCT/US2024/035854 Expired
NIAID E-208-2023-0-EP-01 HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES EP National Stage 22831051.2 Pending
NIA E-183-2024-0-US-02 2-(PIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE ANALOGS AND USES THEREOF US 63/664,442 Expired
NIAID E-208-2023-0-KR-01 HUMAN METAPNEUMOVIRUS VIRAL VECTOR-BASED VACCINES KR National Stage 10-2024-7021286 Pending
NCI E-046-2022-0-EP-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER EP National Stage 22854399.7 Pending
NCATS E-118-2019-0-EP-01 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF EP DIV 24184424.0 Pending
NIDDK E-138-2017-0-EP-01 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS EP DIV 24184468.7 Pending
NCI E-046-2022-0-AU-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER AU National Stage 2022425620 Pending
NIAID E-018-2018-0-TW-01 CHIMERIC VECTORS TW DIV 113123612 Pending
NIAID E-096-2023-0-PC-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PCT PCT PCT/US2024/035244 Expired
NHLBI E-255-2023-0-US-01 AZOLE COMPOUNDS USEFUL AS INHIBITORS OF VOLTAGE-DEPENDENT ANION CHANNEL OLIGOMERIZATION US 63/663,336 Expired
NIAID E-088-2022-0-US-02 Novel Immunogens For Influenza Virus Vaccines US National Stage 18/723,029 Pending
NHGRI E-034-2022-0-US-02 IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA US National Stage 18/723,020 Pending
NCI E-094-2018-0-CN-01 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF CN DIV 202410809055.0 Pending
NCATS E-022-2022-0-US-02 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		US National Stage 18/722,188 Pending
NICHD E-184-2021-0-KR-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO KR National Stage 10-2024-7020525 Pending
NICHD E-184-2021-0-NZ-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO NZ National Stage 812172 Pending
NICHD E-184-2021-0-AU-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO AU National Stage 2022415324 Pending
NCI E-033-2022-0-AU-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS AU National Stage 2022416639 Pending
NCI E-046-2022-0-CA-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY
AGAINST CANCER 		CA National Stage 3241588 Pending
NEI E-208-2024-0-US-01 Suppression of Neurodegenerative Diseases by Single Domain Antibody US 63/660,339 Expired
NIDDK E-085-2022-0-US-02 NEXT GENERATION TRANSPOSOSOMES US National Stage 18/720,218 Pending
NICHD E-184-2021-0-CN-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO CN National Stage 202280082940.2 Pending
NCI E-264-2015-0-EP-01 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4)AND METHODS OF THEIR USE EP DIV 24182233.7 Pending
NCI E-046-2022-0-US-02 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY
AGAINST CANCER 		US National Stage 18/720,347 Pending
NCI E-132-2023-0-PC-01 T CELL RECEPTORS TARGETING RAS WITH G12D, G12R, OR G12V MUTATION PCT PCT PCT/US2024/033766 Expired
NICHD E-184-2021-0-IN-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO IN National Stage 202417045561 Pending
NICHD E-184-2021-0-IL-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO IL National Stage 313530 Pending
NICHD E-184-2021-0-JP-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO JP National Stage 2024-535239 Pending
NLM E-107-2010-2-US-42 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 18/739,955 12338489 Issued PDF
NCI E-113-2021-0-US-02 Bacteriophage Lambda-Vaccine System US National Stage 18/718,766 Pending
NIAAA E-191-2021-0-US-02 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS US National Stage 18/718,691 Pending
NICHD E-184-2021-0-US-02 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO US National Stage 18/718,737 Pending
NICHD E-184-2021-0-EP-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO EP National Stage 22847348.4 Pending
NIAID E-297-2016-2-AU-01 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES AU DIV 2024203948 Pending
NIAAA E-191-2021-0-EP-01 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE
HYDROLASE INHIBITORS 		EP National Stage 22851172.1 Pending
NIAID E-081-2013-4-JP-28 Prefusion RSV F Proteins And Their Use JP DIV 2024-093392 Pending
NIAAA E-191-2021-0-IL-01 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS IL National Stage 313446 Abandoned
NCI E-089-2023-0-PC-01 EPIDITHIODIKETOPIPERAZINE ANALOGS AND METHODS OF USE PCT PCT PCT/US2024/032744 Expired
NIEHS E-184-2023-0-PC-01 METHOD AND APPARATUS FOR CRYOGENIC-ELECTRON MICROSCOPY SAMPLE PREPARATION PCT PCT PCT/US2024/032811 Expired
NCATS E-114-2018-0-US-02 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS US DIV 18/735,506 Pending
NCI E-033-2022-0-CA-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS CA National Stage 3240254 Pending
NICHD E-184-2021-0-ZA-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO ZA National Stage 2024/04426 Pending
NIAID E-228-2016-1-JP-19 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof JP DIV 2024-091170 Abandoned
NICHD E-184-2021-0-CA-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO CA National Stage 3241884 Pending
NHLBI E-146-2023-0-CA-01 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF CA ORD 3240531 Abandoned
NCI E-248-2023-0-US-01 FATTY ACID AND CYCLIZED DERIVATIVES OF THE IMMUNOMODULATORY PEPTIDE RP-182 WITH IMPROVED ANTI-TUMOR ACTIVITY, COMPOSITIONS, AND METHODS OF USE THEREOF US 63/656,535 Expired
NIMH E-214-2023-0-US-01 SYSTEMS AND METHODS FOR ADJUSTABLE CURRENT INDIVIDUALIZED STIMULATION
THERAPY 		US 63/656,515 Expired
NCI E-113-2021-0-EP-01 BACTERIOPHAGE LAMBDA-VACCINE SYSTEM EP National Stage 22847091.0 Issued